Dermata Therapeutics, Inc. Warrant (DRMAW)

• Market cap: $34.5K
• 1 day: 0.00%
• 5 days: 0.00%
• 1 month: -31.50%
• 3 months: -54.18%
• 6 months: 26.85%
• Year to date: -7.43%
• 1 year: -16.97%
• 5 years: -98.77%
• 10 years: -98.77%
• Sector: Healthcare
• Industry: Biotechnology

About: Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.

Employees: 8

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

0.71% less ownership

Funds ownership: 1.81% [Q4 2024] → 1.1% (-0.71%) [Q1 2025]

19% less capital invested

Capital invested by funds: $16.4K [Q4 2024] → $13.2K (-$3.16K) [Q1 2025]

40% less funds holding

Funds holding: 5 [Q4 2024] → 3 (-2) [Q1 2025]

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2